VYNE Therapeutics Inc. (VYNE)
Jul 27, 2026 - VYNE was delisted (reason: merged with YARW)
28.56
+3.11 (12.22%)
Inactive · Last trade price on Jul 27, 2026
VYNE Therapeutics Revenue
VYNE Therapeutics had revenue of $86.00K in the quarter ending March 31, 2026, a decrease of -57.43%. This brings the company's revenue in the last twelve months to $454.00K, down -24.96% year-over-year. In the year 2025, VYNE Therapeutics had annual revenue of $570.00K with 13.77% growth.
Revenue (ttm)
$454.00K
Revenue Growth
-24.96%
P/S Ratio
41.96
Revenue / Employee
$45,400
Employees
10
Market Cap
19.05M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 570.00K | 69.00K | 13.77% |
| Dec 31, 2024 | 501.00K | 77.00K | 18.16% |
| Dec 31, 2023 | 424.00K | -53.00K | -11.11% |
| Dec 31, 2022 | 477.00K | -454.00K | -48.76% |
| Dec 31, 2021 | 931.00K | -20.06M | -95.57% |
| Dec 31, 2020 | 20.99M | 20.55M | 4,638.83% |
| Dec 31, 2019 | 443.00K | -3.15M | -87.68% |
| Dec 31, 2018 | 3.60M | -987.00K | -21.54% |
| Dec 31, 2017 | 4.58M | 3.91M | 579.82% |
| Dec 31, 2016 | 674.00K | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionVYNE News
- 5 days ago - Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves' Disease and Thyroid Eye Disease - Business Wire
- 9 days ago - VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience - GlobeNewsWire
- 11 days ago - VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience - GlobeNewsWire
- 18 days ago - VYNE Therapeutics Slides: Investor presentation - Filings
- 22 days ago - VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience - GlobeNewsWire
- 2 months ago - VYNE Therapeutics Quarterly report: Q1 2026 - Filings
- 5 months ago - VYNE Therapeutics Annual report: Q4 2025 - Filings
- 8 months ago - VYNE Therapeutics Transcript: M&A Announcement - Transcripts